3rd Pneumococcal Symposium web - Sabin Vaccine Institute

More documents

Recommendations

Info

Burden of Disease in Turkey: Seeking Understanding Amidst a Dearth of Data Mehmet Ceyhan of Hacettepe University in Ankara said the main problem with discussing the burden of pneumococcal disease in Turkey is that there is “no surveillance.” However, he said there is research that can offer some insights into Turkey’s situation. Ceyhan and his colleagues are working on one study that, since 2005, has collected 408 cerebrospinal fluid (CSF) samples. In the first year that samples were gathered, there was an outbreak of meningitis caused by meningococcus bacterium. Pneumococcus was found in only 22.5 percent of samples. But, as the epidemic subsided in the subsequent two years a greater proportion of meningitis samples (37%) contained pneumococcus. Ceyhan said researchers are also using data gathered in other countries to calculate an estimate of pneumococcal disease incidence in Turkey. He said such analyses currently suggest that each year in Turkey pneumococcus causes: 250 cases of meningitis, 2,500 cases of bacteremia (bacterial infection of the blood), 250,000 cases of pneumonia, and 2.5 million ear infections or “otitis media” He said there have been studies in Turkey that have attempted to assess the potential effectiveness of the existing 7-valent pneumococcal vaccine. One found it would cover only 40% of locally documented serotypes. But, in that study, FIGURE 2.2 Disease burden projection for Turkey 250 x1 Meningitis 2,500 x10 Bacteremia PREVALANCE 250,000 Pnemonia x100 to 1,000 2,500,000 Otitis Media x1000 to 10,000 From Mehmet Ceyhan, Hacettepe University Adapted from: American Academy of Pediatriks. Pediatriks. 2000;106:367-376 & MMWR. 1997;46:1-24 10 Proceedings of the 3rd Regional Pneumococcal Symposium
FIGURE 2.3 Serotypes in Turkey and 7V PCV AGE LOCATION N YEAR SEROTYPES VACCINE AUTHOR 6-16 Mersin 1440 2007 6,19,1,23,17 40 Aslan G, et al. Indian J Med 2007; 125: 582-7
Page 1 and 2: PROCEEDINGS OF THE Third Regional P
Page 3 and 4: PROCEEDINGS OF THE Third Regional P
Page 5 and 6: Table of Contents Foreword . . . .
Page 7: Foreword The organizers of the Thir
Page 10 and 11: Introduction Tn February 13 and 14,
Page 12 and 13: egional compacts. Khuri-Bulos is pa
Page 14 and 15: FIGURE 1.2 Death rate from Pneumoco
Page 16 and 17: SESSION II Pneumococcal Epidemiolog
Page 20 and 21: “The developing countries have ve
Page 22 and 23: SESSION III Impact of Conjugate Pne
Page 24 and 25: While some studies have evaluated e
Page 26 and 27: FIGURE 3.4 IPD Rates among Alaska N
Page 28 and 29: FIGURE 4.1 Serotype Coverage: Prevn
Page 30 and 31: The PATH Pneumococcal Vaccine Proje
Page 32 and 33: SESSION V Country Spotlights There
Page 34 and 35: Tunisia Amel Kechrid said data on s
Page 36 and 37: FIGURE 6.1 Base-Case PCV cost-effec
Page 38 and 39: “So what are they doing that we a
Page 40 and 41: “The pneumococcal diseases do not
Page 42: List of Speakers NAME ORANGIZATION

3rd Pneumococcal Symposium web - Sabin Vaccine Institute

Create successful ePaper yourself

Delete template?

Save as template?